FDMT4D Molecular Therapeutics Inc
Mkt Cap
$524MVolume
597,682.0052W High
$12.3452W Low
$2.24PE Ratio
-3.02FDMT Fundamentals
Price
$10.75Prev Close
$11.22Open
$10.7750D MA
$8.58Beta
1.29Avg. Volume
873,657.91EPS (Annual)
-$2.98P/B
1.24Rev/Employee
$163.00Wall Street Analysts See a 208.52% Upside in 4D Molecular Therapeutics (FDMT): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 208.5% in 4D Molecular Therapeutics (FDMT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·18d ago
SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag
Sanofi's gene therapy SAR402663 for wet AMD earns FDA fast track status, aiming to speed up development and reduce treatment burden.
Zacks·2mo ago
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -11.36% and -98.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors...
PR Newswire·9mo ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of...
PR Newswire·9mo ago
Kaskela Law LLC Announces Stockholder Investigation of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) and Encourages Investors to Contact the Firm
Kaskela Law LLC announces that it is investigating 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) (4D Molecular) on behalf of the companys stockholders. Since March 2024, shares of 4D Moleculars...
Business Wire·1y ago
FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. (4D Molecular Therapeutics or...
Business Wire·1y ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of...
PR Newswire·1y ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of...
PR Newswire·1y ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of...
PR Newswire·1y ago